← Back to Clinical Trials
RecruitingPhase 4NCT06044493

MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionKidney Transplant
SponsorChong Kun Dang Pharmaceutical
Study TypeINTERVENTIONAL
PhasePhase 4
Enrollment158
SexALL
Min Age19 Years
Max AgeN/A
Start Date2023-11-15
Completion2025-09
Interventions
Myreptic-N TabletMycophenolate mofetil Tablet/Capsule

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this study is to Evaluate the Efficacy and Safety of MYREPTIC-N® or MY-REPT® in Stable Patients after Kidney Transplant Recipients

Eligibility Criteria

Inclusion Criteria: 1. Over 19 years old 2. Patients who at least 1 year after kidney transplant 3. serum creatinine ≤2.3 mg/dL 4. Patients on immunosuppressive maintenance therapy using combination of Calcineurin Inhibitor and Mycophenolate Mofetil after kidney transplantation Exclusion Criteria: 1. Patients who had received treatment Acute rejection within 4 weeks 2. Patients who had discontinued corticosteroid within 4 weeks 3. At the time of Screening * Treatment with active liver disease or Liver function test(T-bilirubin, AST, ALT)is over 3 times than upper normal limit * WBC\< 2,500/mm\^3, or platelet \< 75,000/mm\^3, or ANC \< 1,300/ mm\^3 4. In investigator's judgement

Related Trials